Next-generation T-cell therapies for cancer.
Tmunity Therapeutics developed next-generation engineered T-cell therapies (CAR-T and TCR-T) for solid tumors and hematologic malignancies in oncology. The company collaborated with biopharma partners and clinical centers before being acquired by Kite, a Gilead Company.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountDec 2022
Oct 2019
Jan 2018
Dec 2015
Create a free account to see which investors have funded this company.
Create Free Account
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Clinical-stage biotechnology company developing T-cell engager therapeutics for autoimmune and in...
Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...
